Publication: Human-induced pluripotent stem cell-atrial-specific cardiomyocytes and atrial fibrillation
0
0
Issued Date
2022
Resource Type
Language
eng
File Type
application/pdf
ISSN
23078960
Rights Holder(s)
Scopus
Bibliographic Citation
Pertanika Journal of Tropical Agricultural Science. Vol 45, No.4 (2022), p.1161-1175
Suggested Citation
Leowattana W., Leowattana T., Leowattana P. Human-induced pluripotent stem cell-atrial-specific cardiomyocytes and atrial fibrillation. Pertanika Journal of Tropical Agricultural Science. Vol 45, No.4 (2022), p.1161-1175. doi:10.12998/wjcc.v10.i27.9588 Retrieved from: https://hdl.handle.net/20.500.14740/9329
Author(s)
Abstract
Patient-specific human-induced pluripotent stem cell-derived atrial cardiomyocytes (hiPSC-aCMs) may be produced, genome-edited, and differentiated into multiple cell types for regenerative medicine, disease modeling, drug testing, toxicity screening, and three-dimensional tissue fabrication. There is presently no complete model of atrial fibrillation (AF) available for studying human pharmacological responses and evaluating the toxicity of potential medication candidates. It has been demonstrated that hiPSC-aCMs can replicate the electrophysiological disease phenotype and genotype of AF. The hiPSC-aCMs, however, are immature and do not reflect the maturity of aCMs in the native myocardium. Numerous laboratories utilize a variety of methodologies and procedures to improve and promote aCM maturation, including electrical stimulation, culture duration, biophysical signals, and changes in metabolic variables. This review covers the current methods being explored for use in the maturation of patient-specific hiPSC-aCMs and their application towards a personalized approach to the pharmacologic therapy of AF © The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved